Taken together, many studies suggest that several solid tumors, especially advanced stage non-small cell lung cancer (NSCLC) [50] and renal cell cancer (RCC) [51], are responsive to both anti-VEGF and anti-PD-1/PD-L1 therapies. This evidence concerns the gene PDCD1 and renal cell adenocarcinoma.